Dextran 40 is commonly used for use in the adjunctive treatment of shock or impending shock due to hemorrhage, burns, surgery or other trauma. It is not indicated as a replacement for whole blood or blood components if they are available. It should not replace other forms of therapy known to be of value in the treatment of shock.
It is also indicated for use as a priming fluid, either as a sole prime or as an additive, in pump oxygenators during extracorporeal circulation.
It is also indicated for use in prophylaxis of venous thrombosis and pulmonary embolism in patients undergoing procedures known to be associated with a high incidence of thromboembolic complications, such as hip surgery.
Dextran 40 is administered through I.V. infusion by your doctor.
Dextran 40 is best stored at room temperature away from direct light and moisture. To prevent drug damage, you should not store Dextran 40 in the bathroom or the freezer. There may be different brands of Dextran 40 that may have different storage needs. It is important to always check the product package for instructions on storage, or ask your pharmacist. For safety, you should keep all medicines away from children and pets.
You should not flush Dextran 40 down the toilet or pour them into a drain unless instructed to do so. It is important to properly discard this product when it is expired or no longer needed. Consult your pharmacist for more details about how to safely discard your product.
The possibility of circulatory overload should be kept in mind. Special care should be exercised in patients with impaired renal clearance of dextran. When the risk of pulmonary edema and/or congestive heart failure may be increased, dextran should be used with caution.
In patients with normal hemostasis, dosage of LMD (dextran 40) approximating 15 mL/kg of body weight may prolong bleeding time and depress platelet function.
Dosages in this range also markedly decrease factor VIII, and decrease factors V and IX to a greater degree than would be expected to occur from hemodilution alone.
Since these changes tend to be more pronounced following trauma or major surgery, patients should be observed for early signs of bleeding complications.
Since increased rouleaux formation may occur in the presence of dextran, it is recommended that blood samples be drawn for typing and cross-matching prior to the infusion of dextran and reserved for subsequent use if necessary. If blood is drawn after infusion of dextran, the saline agglutination and indirect antiglobulin methods may be used for typing and cross-matching. Difficulty may be encountered when proteolytic enzyme techniques are used to match blood.
Consideration should be given to withdrawal of blood for chemical laboratory tests prior to initiating therapy with dextran because of the following:
Solutions containing dextrose should be used with caution in patients with known subclinical or overt diabetes mellitus.
Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions, to patients receiving corticosteroids or corticotropin.
Do not administer unless solution is clear and container is undamaged. Discard unused portion.
There are no adequate studies in women for determining risk when using Dextran 40 during pregnancy or while breastfeeding. Please always consult with your doctor to weigh the potential benefits and risks before taking Dextran 40. Dextran 40 is pregnancy risk category C, according to the US Food and Drug Administration (FDA).
FDA pregnancy risk category reference below:
Breastfeeding
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when 10% LMD (dextran 40) in dextrose or sodium chloride is administered to a nursing woman.
Some side effects can occur when using this drug, including:
Not everyone experiences these side effects. There may be some side effects not listed above. If you have any concerns about a side-effect, please consult your doctor or pharmacist.
Dextran 40 may interact with other drugs that you are currently taking, which can change how your drug works or increase your risk for serious side effects. To avoid any potential drug interactions, you should keep a list of all the drugs you are using (including prescription drugs, nonprescription drugs, and herbal products) and share it with your doctor and pharmacist. For your safety, do not start, stop, or change the dosage of any drugs without your doctor’s approval.
Dextran 40 may interact with food or alcohol by altering the way the drug works or increase the risk for serious side effects. Please discuss with your doctor or pharmacist any potential food or alcohol interactions before using this drug.
Dextran 40 may interact with your health condition. This interaction may worsen your health condition or alter the way the drug works. It is important to always let your doctor and pharmacist know all the health conditions you currently have.
The information provided is not a substitute for any medical advice. You should ALWAYS consult with your doctor or pharmacist before using Dextran 40.
Shock
The total dosage does not exceed 20 ml/kg for adults and adolescents, during the first 24 hours. The first 10 ml/kg may be infused as rapidly as necessary to effect improvement.
It is strongly recommended that central venous pressure be monitored frequently during the initial infusion of the drug. Should therapy continue beyond 24 hours, subsequent dosage should not exceed 10 mL/kg per day and therapy should not continue beyond five days.
Extracorporeal perfusion
The dosage of LMD used will vary with the volume of the pump oxygenator. LMD can serve as a sole primer or as an additive to other priming fluids.
For adults and adolescents, generally 10 to 20 ml of a 10% solution (1 to 2 g) of LMD per kilogram of body weight are added to the perfusion circuit. Usually total dosage should not exceed 2 g/kg of body weight.
Prophylaxis of venous thrombosis and thromboembolism
The dosage of LMD for adults and adolescents, should be chosen according to the risk of thromboembolic complications, e.g., type of surgery and duration of immobilization.
In general, treatment should be initiated during surgery; 500 to 1,000 ml (approximately 10 ml/kg of body weight) should be administered on the day of operation.
Treatment should be continued at a dose of 500 ml daily for an additional two to three days; then, according to the risk of complications, 500 ml may be given every second or third day during the period of risk, for up to two weeks.
The recommended dose is 5 ml per kg body weight and 10 ml per kg.
Dextran 40 is available in the following dosage forms and strengths:
In case of an emergency or an overdose, call your local emergency services or go to your nearest emergency room.
If you miss a dose of Dextran 40, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and take your regular dose as scheduled. Do not take a double dose.